Results 51 to 60 of about 19,287 (163)
Gastroenterology Research and Practice, 2013 Background. Despite improvement in treatment, the prognosis of hepatocellular carcinoma (HCC) remains disastrous. Cancer stem cells (CSCs) may be responsible for cancer malignant behaviors.
Guang Zhang +5 more
doaj +1 more source
Suppression of ABCG2 mediated MDR in vitro and in vivo by a novel inhibitor of ABCG2 drug transport
Pharmacological Research, 2017 Cancer is a disease whose treatment is often limited due to the development of a phenomenon known as multidrug resistance (MDR). There is an immense demand for development of novel agents that can overcome the MDR in cancer. A group of transmembrane proteins called ATP-binding cassette transporters, present ubiquitously in the human body possesses a ...
Atish, Patel +9 more
openaire +2 more sources
Expression and function of ABCG2 and XIAP in glioblastomas [PDF]
Journal of Neuro-Oncology, 2017 Despite multimodal treatment that includes surgery, radiation and chemotherapy, virtually all glioblastomas (GBM) recur, indicating that these interventions are insufficient to eradicate all malignant cells. To identify potential new therapeutic targets in GBMs, we examined the expression and function of proteins that are associated with therapy ...
Ivette F. Emery +8 more
openaire +3 more sources
2‐Carboranylquinazoline: The Path to an ABCG2 Inhibitor
ChemMedChem, 2023 AbstractThe role of ATP‐binding cassette (ABC) transporter‐mediated multidrug resistance (MDR) in anti‐cancer therapy is often challenging, frequently leading to inefficiency of treatments. Cancer cells exploit efflux transporters, like the breast cancer resistance protein (BCRP, ABCG2), to secrete chemotherapeutic substances.
Philipp Stockmann +4 more
openaire +3 more sources
Neoplasia: An International Journal for Oncology Research, 2009 ABCG2 is an efflux transporter conferring multidrug resistance (MDR) on cancer cells. However, the initial molecular events leading to its up-regulation in MDR tumor cells are poorly understood.
Eran E. Bram +3 more
doaj +1 more source
SLCO1B1 and ABCG2 Gene Polymorphisms in a Thai Population
Pharmacogenomics and Personalized Medicine, 2020 Punyabhorn Rattanacheeworn,1,2 Monpat Chamnanphon,1 Siriwan Thongthip,3 Wonngarm Kittanamongkolchai,3 Natavudh Townamchai,1,4 Yingyos Avihingsanon,1,4 Udomsak Udomnilobol,5 Thomayant Prueksaritanont,5 Suree Jianmongkol,5,6 Pajaree Chariyavilaskul1,2 ...
Rattanacheeworn P +9 more
doaj
Frontiers in Oncology, 2020 Sitravatinib, also called MGCD516 or MG-516, is a broad-spectrum tyrosine kinase inhibitor (TKI) under phase III clinical evaluation. Herein, we explored the activity of sitravatinib toward multidrug resistance (MDR) by emphasizing its inhibitory effect ...
Yuqi Yang +10 more
doaj +1 more source
Indian Journal of Pathology and MicrobiologyObjectives: For oral squamous cell carcinoma (OSCC), we are likely at a juncture in clinical management, where the benefits of therapies are beginning to plateau.
Trupti I. Trivedi +2 more
doaj +1 more source
Expression and significance of CD133 and ABCG2 in endometriosis
Clinical and Experimental Obstetrics & Gynecology, 2015 Endometriosis is a common gynecological disease and exact pathogenesis is still unclear. Recently, an increasing interest has been given to the potential role of stem cells in the development of endometriosis. The aim of this study was to test the expression of sterness-related markers CD133 and ABCG2 in endometriosis.CD133 and ABCG2 protein expression
S, Liu, J, Zhou, J, Wen
openaire +2 more sources
Revisiting strategies to target ABC transporter-mediated drug resistance in CNS cancer
Cancer Biology & MedicineA significant number of anticancer drugs fail to treat primary and metastatic brain tumors primarily because of the complex blood-brain barrier (BBB) and overexpression of ATP-binding cassette (ABC) transporters, which decrease drug penetration into the ...
Haneen Amawi +9 more
doaj +1 more source